File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Esomeprazole With Aspirin Versus Clopidogrel for Prevention of Recurrent Gastrointestinal Ulcer Complications

TitleEsomeprazole With Aspirin Versus Clopidogrel for Prevention of Recurrent Gastrointestinal Ulcer Complications
Authors
Issue Date2006
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cgh
Citation
Clinical Gastroenterology And Hepatology, 2006, v. 4 n. 7, p. 860-865 How to Cite?
AbstractBackground & Aims: The role of clopidogrel in patients at risk for gastrointestinal complications is uncertain, although it has been recommended for patients who have gastrointestinal intolerance to aspirin. We tested the hypothesis that clopidogrel is as effective as esomeprazole and aspirin in preventing recurrences of ulcer complications. Methods: This was a prospective, double-blind, randomized, controlled study of 170 patients who developed ulcer bleeding after the use of low-dose aspirin between November 2002 and January 2005. After healing of ulcers and eradication of Helicobacter pylori, if present, patients were assigned randomly to treatment with esomeprazole 20 mg/day and aspirin 100 mg/day (n = 86) or clopidogrel 75 mg/day (n = 84) for 52 weeks. The primary end point was recurrent ulcer complications. Results: During a median follow-up period of 52 weeks, no patient in the esomeprazole group, as compared with 9 patients in the clopidogrel group, developed recurrent ulcer complications. The cumulative incidences of recurrent ulcer complications were 0% in patients receiving esomeprazole and aspirin and 13.6% in patients receiving clopidogrel (absolute difference, 13.6%; 95% confidence interval for the difference, 6.3-20.9; log-rank test, P = .0019). Conclusions: The combination of esomeprazole and aspirin is superior to clopidogrel in preventing ulcer complications in patients who have a past history of aspirin-related peptic ulcer bleeding. © 2006 American Gastroenterological Association.
Persistent Identifierhttp://hdl.handle.net/10722/76718
ISSN
2015 Impact Factor: 7.68
2015 SCImago Journal Rankings: 2.744
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, Ken_HK
dc.contributor.authorChu, Ken_HK
dc.contributor.authorHui, Wen_HK
dc.contributor.authorWong, BCen_HK
dc.contributor.authorHung, Wen_HK
dc.contributor.authorLoo, Cen_HK
dc.contributor.authorHu, WHen_HK
dc.contributor.authorChan, AOen_HK
dc.contributor.authorKwok, Ken_HK
dc.contributor.authorFung, Ten_HK
dc.contributor.authorWong, Jen_HK
dc.contributor.authorLam, Sen_HK
dc.date.accessioned2010-09-06T07:24:12Z-
dc.date.available2010-09-06T07:24:12Z-
dc.date.issued2006en_HK
dc.identifier.citationClinical Gastroenterology And Hepatology, 2006, v. 4 n. 7, p. 860-865en_HK
dc.identifier.issn1542-3565en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76718-
dc.description.abstractBackground & Aims: The role of clopidogrel in patients at risk for gastrointestinal complications is uncertain, although it has been recommended for patients who have gastrointestinal intolerance to aspirin. We tested the hypothesis that clopidogrel is as effective as esomeprazole and aspirin in preventing recurrences of ulcer complications. Methods: This was a prospective, double-blind, randomized, controlled study of 170 patients who developed ulcer bleeding after the use of low-dose aspirin between November 2002 and January 2005. After healing of ulcers and eradication of Helicobacter pylori, if present, patients were assigned randomly to treatment with esomeprazole 20 mg/day and aspirin 100 mg/day (n = 86) or clopidogrel 75 mg/day (n = 84) for 52 weeks. The primary end point was recurrent ulcer complications. Results: During a median follow-up period of 52 weeks, no patient in the esomeprazole group, as compared with 9 patients in the clopidogrel group, developed recurrent ulcer complications. The cumulative incidences of recurrent ulcer complications were 0% in patients receiving esomeprazole and aspirin and 13.6% in patients receiving clopidogrel (absolute difference, 13.6%; 95% confidence interval for the difference, 6.3-20.9; log-rank test, P = .0019). Conclusions: The combination of esomeprazole and aspirin is superior to clopidogrel in preventing ulcer complications in patients who have a past history of aspirin-related peptic ulcer bleeding. © 2006 American Gastroenterological Association.en_HK
dc.languageengen_HK
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cghen_HK
dc.relation.ispartofClinical Gastroenterology and Hepatologyen_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshAnti-Ulcer Agents - administration & dosageen_HK
dc.subject.meshAspirin - administration & dosageen_HK
dc.subject.meshCohort Studiesen_HK
dc.subject.meshDouble-Blind Methoden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOmeprazole - administration & dosageen_HK
dc.subject.meshPeptic Ulcer Hemorrhage - etiology - prevention & controlen_HK
dc.subject.meshPlatelet Aggregation Inhibitors - administration & dosageen_HK
dc.subject.meshRecurrence - prevention & controlen_HK
dc.subject.meshStomach Ulcer - complicationsen_HK
dc.subject.meshTiclopidine - administration & dosage - analogs & derivativesen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleEsomeprazole With Aspirin Versus Clopidogrel for Prevention of Recurrent Gastrointestinal Ulcer Complicationsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1542-3565&volume=4&spage=860&epage=865&date=2006&atitle=Esomeprazole+with+aspirin+versus+clopidogrel+for+prevention+of+recurrent+gastrointestinal+ulcer+complicationsen_HK
dc.identifier.emailChu, K: chukm@hkucc.hku.hken_HK
dc.identifier.emailWong, BC: bcywong@hku.hken_HK
dc.identifier.emailWong, J: jwong@hkucc.hku.hken_HK
dc.identifier.authorityChu, K=rp00435en_HK
dc.identifier.authorityWong, BC=rp00429en_HK
dc.identifier.authorityWong, J=rp00322en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.cgh.2006.04.019en_HK
dc.identifier.pmid16797240-
dc.identifier.scopuseid_2-s2.0-33745610044en_HK
dc.identifier.hkuros117614en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33745610044&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume4en_HK
dc.identifier.issue7en_HK
dc.identifier.spage860en_HK
dc.identifier.epage865en_HK
dc.identifier.isiWOS:000239202600012-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLai, K=7402135595en_HK
dc.identifier.scopusauthoridChu, K=7402453538en_HK
dc.identifier.scopusauthoridHui, W=7103196477en_HK
dc.identifier.scopusauthoridWong, BC=7402023340en_HK
dc.identifier.scopusauthoridHung, W=26027012100en_HK
dc.identifier.scopusauthoridLoo, C=7103026584en_HK
dc.identifier.scopusauthoridHu, WH=25932937100en_HK
dc.identifier.scopusauthoridChan, AO=7403167965en_HK
dc.identifier.scopusauthoridKwok, K=7102194177en_HK
dc.identifier.scopusauthoridFung, T=13612072400en_HK
dc.identifier.scopusauthoridWong, J=8049324500en_HK
dc.identifier.scopusauthoridLam, S=7402279800en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats